GFM
GF Fund Management Portfolio holdings
AUM
$4.97B
This Quarter Return
+7.58%
1 Year Return
–
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$4.62B
AUM Growth
–
Cap. Flow
+$4.62B
Cap. Flow
% of AUM
100%
Top 10 Holdings %
Top 10 Hldgs %
48.03%
Holding
637
New
637
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
NVIDIA
NVDA
|
$390M |
| 2 |
Apple
AAPL
|
$374M |
| 3 |
Microsoft
MSFT
|
$322M |
| 4 |
Amazon
AMZN
|
$234M |
| 5 |
Meta Platforms (Facebook)
META
|
$194M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Technology | 45.53% |
| 2 | Consumer Discretionary | 17.29% |
| 3 | Communication Services | 14.35% |
| 4 | Healthcare | 6.6% |
| 5 | Consumer Staples | 4.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
501
Evolus
EOLS
$495M
| $14.7K | ﹤0.01% |
+1,330
| New | +$14.7K |
|
502
Relay Therapeutics
RLAY
$710M
| $14.5K | ﹤0.01% |
+3,515
| New | +$14.5K |
|
|
TECX
503
Tectonic Therapeutic, Inc. Common Stock
TECX
$314M
| $14.3K | ﹤0.01% |
+310
| New | +$14.3K |
|
|
ORKA
504
Oruka Therapeutics, Inc. Common Stock
ORKA
$612M
| $14.3K | ﹤0.01% |
+735
| New | +$14.3K |
|
505
Kura Oncology
KURA
$713M
| $14.2K | ﹤0.01% |
+1,633
| New | +$14.2K |
|
|
CRGX
506
DELISTED
CARGO Therapeutics
CRGX
| $13.9K | ﹤0.01% |
+966
| New | +$13.9K |
|
|
RAPP
507
Rapport Therapeutics
RAPP
$524M
| $13.6K | ﹤0.01% |
+768
| New | +$13.6K |
|
508
Entrada Therapeutics
TRDA
$201M
| $13.6K | ﹤0.01% |
+785
| New | +$13.6K |
|
509
Humacyte
HUMA
$226M
| $13.6K | ﹤0.01% |
+2,685
| New | +$13.6K |
|
|
INN
510
Summit Hotel Properties
INN
$614M
| $13.4K | ﹤0.01% |
+1,953
| New | +$13.4K |
|
511
Keros Therapeutics
KROS
$633M
| $13.4K | ﹤0.01% |
+844
| New | +$13.4K |
|
|
MESO
512
Mesoblast
MESO
$1.84B
| $13.3K | ﹤0.01% |
+671
| New | +$13.3K |
|
|
PLYM
513
Plymouth Industrial REIT
PLYM
$998M
| $13.1K | ﹤0.01% |
+737
| New | +$13.1K |
|
514
Arbutus Biopharma
ABUS
$805M
| $13K | ﹤0.01% |
+3,979
| New | +$13K |
|
515
SITE Centers
SITC
$490M
| $13K | ﹤0.01% |
+850
| New | +$13K |
|
|
BCYC
516
Bicycle Therapeutics
BCYC
$496M
| $12.9K | ﹤0.01% |
+924
| New | +$12.9K |
|
517
Mineralys Therapeutics
MLYS
$2.31B
| $12.9K | ﹤0.01% |
+1,045
| New | +$12.9K |
|
|
GRAL
518
GRAIL, Inc. Common Stock
GRAL
$1.33B
| $12.5K | ﹤0.01% |
+699
| New | +$12.5K |
|
|
GOOD
519
Gladstone Commercial Corp
GOOD
$616M
| $12.5K | ﹤0.01% |
+767
| New | +$12.5K |
|
520
Stoke Therapeutics
STOK
$1.13B
| $12.3K | ﹤0.01% |
+1,112
| New | +$12.3K |
|
521
Omeros
OMER
$284M
| $12K | ﹤0.01% |
+1,217
| New | +$12K |
|
522
Oric Pharmaceuticals
ORIC
$1.06B
| $12K | ﹤0.01% |
+1,482
| New | +$12K |
|
523
Phathom Pharmaceuticals
PHAT
$875M
| $11.7K | ﹤0.01% |
+1,436
| New | +$11.7K |
|
524
Annexon
ANNX
$238M
| $11.5K | ﹤0.01% |
+2,238
| New | +$11.5K |
|
525
Coinbase
COIN
$76.8B
| $11.2K | ﹤0.01% |
+45
| New | +$11.2K |
|